Imcivree (setmelanotide) is a once-daily subcutaneous injection that restores melanocortin-4 receptor signaling in patients with specific rare genetic causes of obesity. It is approved for POMC, PCSK1, LEPR deficiency, and Bardet-Biedl syndrome. Weight loss averages 8 to 25 percent depending on the genetic diagnosis. Common side effects include injection-site reactions, skin darkening, nausea, and spontaneous erections.
What Imcivree Is
Imcivree is the brand name for setmelanotide, a synthetic 8-amino-acid peptide that selectively activates the melanocortin-4 receptor (MC4R) in the hypothalamus. The MC4R pathway is central to satiety and energy balance: when alpha-melanocyte-stimulating hormone (alpha-MSH) binds MC4R, the brain perceives fullness and reduces hunger. Patients with mutations in genes upstream of MC4R (POMC, PCSK1, LEPR) or in pathways converging on MC4R signaling (BBS) lack this satiety input and experience extreme, persistent hunger from early childhood. Setmelanotide bypasses the broken pathway and stimulates MC4R directly.
It was developed by Rhythm Pharmaceuticals and first FDA approved in November 2020 for POMC, PCSK1, and LEPR deficiency. The label was expanded in June 2022 to include Bardet-Biedl syndrome.
Who Qualifies
Imcivree is indicated for chronic weight management in patients with obesity due to one of the following genetically confirmed conditions:
- POMC deficiency — bi-allelic mutations in the POMC gene
- PCSK1 deficiency — bi-allelic mutations in PCSK1
- LEPR deficiency — bi-allelic mutations in the leptin receptor gene
- Bardet-Biedl syndrome — clinical diagnosis plus genetic confirmation in one of more than 20 BBS-associated genes
Age cutoffs: 2 years and older for the three monogenic deficiencies; 6 years and older for BBS. Confirmatory genetic testing is required and is offered free of charge by the manufacturer through the Uncovering Rare Obesity program.
Imcivree is not approved for general obesity, hypothalamic obesity, or other non-MC4R-pathway causes.
How It Works
In a healthy MC4R pathway:
- Leptin from fat tissue signals fat stores to the brain.
- Leptin activates POMC neurons in the hypothalamic arcuate nucleus.
- POMC is cleaved by PCSK1 (and other enzymes) to make alpha-MSH.
- Alpha-MSH binds MC4R, producing satiety.
If POMC, PCSK1, or LEPR is broken, the chain fails at an upstream step and MC4R never gets activated — the patient experiences hyperphagia (extreme hunger) and severe early-onset obesity. Setmelanotide replaces alpha-MSH at MC4R, restoring the satiety signal regardless of where the upstream block is.
Dosing
Imcivree is given by subcutaneous injection, once daily, into the abdomen, thigh, or upper arm. Starting dose and titration depend on age:
| Age | Starting Dose | Target Maintenance |
|---|---|---|
| ≥12 years | 2 mg daily | 3 mg daily (max) |
| 6-11 years | 1 mg daily | Up to 3 mg daily |
| 2-5 years | 0.5 mg daily | Up to 2 mg daily |
Dose is titrated upward every 2 weeks as tolerated and based on hunger and weight response. The pen is stored refrigerated and brought to room temperature before injection. Sites are rotated to reduce site reactions.
Expected Weight Loss
| Population | Median Weight Loss at 1 Year | ≥10% Loss |
|---|---|---|
| POMC or PCSK1 deficiency | ~25% | ~80% |
| LEPR deficiency | ~12% | ~45% |
| Bardet-Biedl syndrome | ~8% | ~30% |
Hunger scores (measured on validated 0-10 scales) typically dropped by 40 to 50 percent — a clinically dramatic change for patients who had described constant, overwhelming hunger before treatment.
Common Side Effects
- Injection site reactions — redness, itching, induration; reported in roughly 75% of users
- Skin hyperpigmentation — generalized darkening of skin, lips, gums, hair, and existing moles; 50 to 60% of users
- New nevi or darkening of existing nevi — pre-treatment and periodic full-body skin examinations are recommended
- Nausea, diarrhea, abdominal pain — common in first months
- Headache
- Spontaneous penile erections — through MC4R activity on neural pathways; usually transient
- Disturbances in sexual arousal in females
Serious Risks
- Depression and suicidal ideation — monitor mental health throughout treatment
- Skin malignancy concern — chronic MC1R activation theoretically increases melanoma risk; pre-treatment and ongoing dermatologic surveillance is part of REMS-like recommendations
- Pediatric growth and puberty — long-term effects in children are still being studied
- Pregnancy — limited human data; weight loss during pregnancy is not recommended
How Imcivree Differs from Other Anti-Obesity Drugs
| Aspect | Imcivree | GLP-1 RAs (Wegovy/Zepbound) | Qsymia/Contrave |
|---|---|---|---|
| Mechanism | MC4R agonist | GLP-1 receptor agonist | CNS appetite suppression |
| Target population | Specific rare mutations | General obesity | General obesity |
| Genetic testing | Required | Not required | Not required |
| Route | Daily SC injection | Weekly SC injection (oral pill | Oral pill |
| Annual cost | ~$300,000 | ~$15,000-20,000 | ~$1,200-9,000 |
| Insurance coverage | Specialty pharmacy | Variable | Variable |
Genetic Testing and Diagnosis
Before prescribing, clinicians order a panel testing the MC4R pathway genes. Rhythm Pharmaceuticals sponsors a no-cost genetic testing program (Uncovering Rare Obesity) for patients with severe early-onset obesity (often BMI Z-score over +3, onset before age 5) and clinical features such as hyperphagia and pituitary or pigmentation abnormalities. A positive test for a qualifying bi-allelic mutation in POMC, PCSK1, or LEPR — or a clinical and genetic diagnosis of BBS — establishes eligibility.
Cost and Access
List price for Imcivree is roughly 25,000 dollars per month or 300,000 dollars per year for adult dosing. Pediatric doses cost less but are still substantial. The drug is distributed only through specialty pharmacy. Rhythm’s patient support program assists with insurance authorization, copay support for commercial plans, and a free drug program for eligible uninsured or underinsured patients.
Because the target population is very small (estimated low hundreds of diagnosed patients in the US for POMC/PCSK1/LEPR; a few thousand for BBS), payer concerns about per-patient cost have been somewhat offset by total spend remaining limited.
Practical Considerations
- Genetic testing comes before any prescription.
- Plan for daily injection logistics — refrigeration, site rotation, supply.
- Schedule a baseline dermatology exam and annual skin checks.
- Track hunger scores in addition to weight; hunger improvement is often a more sensitive marker of response.
- Discuss mood monitoring and emergency contact plans.
- Specialty pharmacy refills and insurance navigation typically involve the manufacturer’s case manager.
Related Reading
See our anti-obesity medications overview, our discussion of Qsymia and other oral options, and our pillar on treatment options for prediabetes and type 2 diabetes.
The Bottom Line
Imcivree (setmelanotide) is a once-daily MC4R-agonist injection approved for patients with specific rare genetic obesity disorders — POMC, PCSK1, LEPR deficiency, and Bardet-Biedl syndrome. It produces 8 to 25 percent weight loss at one year depending on the genetic diagnosis and substantially reduces hunger scores. Common side effects are injection-site reactions, skin hyperpigmentation, nausea, and spontaneous erections. Genetic testing is required, and list price approaches 300,000 dollars per year. For the small population it serves, Imcivree may be the first effective treatment for a lifelong condition. Talk to your doctor about whether you or your child meet the criteria.
